54.46
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché SNY Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$54.13
Aprire:
$54.03
Volume 24 ore:
1.41M
Relative Volume:
0.60
Capitalizzazione di mercato:
$136.54B
Reddito:
$48.03B
Utile/perdita netta:
$6.06B
Rapporto P/E:
21.80
EPS:
2.4983
Flusso di cassa netto:
$9.91B
1 W Prestazione:
-0.07%
1M Prestazione:
+5.36%
6M Prestazione:
-1.38%
1 anno Prestazione:
+13.65%
Sanofi Adr Stock (SNY) Company Profile
Nome
Sanofi Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta SNY con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
SNY
Sanofi Adr
|
54.46 | 136.54B | 48.03B | 6.06B | 9.91B | 2.4983 |
![]()
LLY
Lilly Eli Co
|
873.68 | 830.35B | 45.04B | 10.59B | 414.30M | 11.71 |
![]()
NVO
Novo Nordisk Adr
|
88.08 | 390.99B | 42.09B | 14.65B | 10.11B | 3.2833 |
![]()
ABBV
Abbvie Inc
|
202.08 | 356.74B | 56.33B | 4.28B | 17.83B | 2.40 |
![]()
JNJ
Johnson Johnson
|
162.30 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
![]()
MRK
Merck Co Inc
|
89.50 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-01-30 | Aggiornamento | Deutsche Bank | Sell → Hold |
2024-07-26 | Reiterato | Argus | Buy |
2024-01-23 | Iniziato | Morgan Stanley | Equal-Weight |
2024-01-16 | Ripresa | UBS | Buy |
2023-12-05 | Downgrade | JP Morgan | Overweight → Neutral |
2023-10-30 | Downgrade | Stifel | Buy → Hold |
2023-09-06 | Aggiornamento | Berenberg | Hold → Buy |
2023-07-14 | Iniziato | HSBC Securities | Buy |
2023-04-28 | Downgrade | Deutsche Bank | Hold → Sell |
2023-03-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
2022-12-13 | Ripresa | Morgan Stanley | Overweight |
2022-08-12 | Aggiornamento | Deutsche Bank | Sell → Hold |
2022-08-09 | Downgrade | UBS | Buy → Neutral |
2022-05-23 | Iniziato | SVB Leerink | Outperform |
2021-09-27 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
2021-01-15 | Iniziato | Deutsche Bank | Sell |
2020-09-29 | Iniziato | Berenberg | Hold |
2020-03-17 | Aggiornamento | Barclays | Underweight → Equal Weight |
2020-03-11 | Aggiornamento | Goldman | Neutral → Buy |
2020-02-11 | Iniziato | SVB Leerink | Mkt Perform |
2020-01-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
2019-09-20 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2019-09-03 | Iniziato | Bernstein | Outperform |
2019-08-14 | Aggiornamento | UBS | Neutral → Buy |
2018-12-11 | Aggiornamento | Jefferies | Hold → Buy |
2018-11-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
2018-10-09 | Iniziato | Guggenheim | Neutral |
2018-09-10 | Aggiornamento | BofA/Merrill | Neutral → Buy |
2018-08-10 | Aggiornamento | Citigroup | Neutral → Buy |
2018-03-23 | Aggiornamento | Liberum | Hold → Buy |
2018-01-23 | Downgrade | Barclays | Equal Weight → Underweight |
2017-12-06 | Downgrade | BofA/Merrill | Buy → Neutral |
2017-12-01 | Downgrade | Morgan Stanley | Overweight → Underweight |
2017-11-15 | Aggiornamento | Barclays | Underweight → Equal Weight |
2017-08-30 | Aggiornamento | HSBC Securities | Reduce → Hold |
Mostra tutto
Sanofi Adr Borsa (SNY) Ultime notizie
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease - GlobeNewswire Inc.
Validea Detailed Fundamental AnalysisSNY - Nasdaq
Harrow Earns Relative Strength Rating Upgrade - Inkl
Sanofi ADR Earns RS Rating Upgrade - Investor's Business Daily
Newmont Earns RS Rating Upgrade - Inkl
What was Skechers U S A, Inc (SKX)’s performance in the last session? - US Post News
Sanofi ADR (SNY) requires closer examination - US Post News
Sanofi ADR (SNY): A Technical Analysis - The News Heater
GNPX’s Market Whiplash: -38.94% YTD Decline, -42.28% Plunge in 30 Days - The InvestChronicle
Applied Materials Inc’s Banking’s 100-Day Moving Average at 182.60: Will the Stock Break Through? - The InvestChronicle
ESPR’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils Dividend - Investor's Business Daily
Waltham biotech plans to raise $150M in IPO this week - The Business Journals
Sanofi Reports Strong Q4 Sales Growth, Plans €5 Billion Buyback in 2025 - GuruFocus.com
Sanofi ADR earnings beat by $0.53, revenue fell short of estimates - Investing.com South Africa
Sanofi ADR (SNY) Recovers 15.33% From Low: Are We There Yet? - Stocks Register
Sanofi Earnings: Positive Outlook for 2025 Due to Accelerating Pipeline Development - Morningstar
Sanofi: Informations relatives au nombre de droits de vote et d'actions - GlobeNewswire Inc.
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
AECOM (NYSE: ACM) Is A Blank Check For Growth - Stocks Register
Shares Of Pennymac Mortgage Investment Trust (NYSE: PMT): Are They Overvalued Compared To Others? - Stocks Register
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
Gsk Plc ADR (GSK-N) QuotePress Release - The Globe and Mail
3 Pharma Stocks To Buy As California Sounds The Alarm On Bird Flu Cases - Barchart
Communiqué de presse - GlobeNewswire Inc.
Teva Pharmaceutical ADR Clears Technical Benchmark, Hitting 90-Plus RS Rating - Investor's Business Daily
10 Best Blue-Chip Stocks to Buy for the Long Term - Morningstar
Teva Catapults 26%, Hitting A Six-Year High, After Scoring A Win With Sanofi-Tied Drug - Investor's Business Daily
What Did We Find About Insider Trading At Sanofi ADR (NASDAQ: SNY)? - Stocks Register
Sanofi Adr Azioni (SNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):